Table 4.
Unadjusted and adjusted analyses for the risk of NAFLD in all subjects.
| Unadjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | |
|---|---|---|---|---|
| Age | 1.05 (1.03–1.07) | <0.001 | 1.00 (0.97–1.03) | 0.989 |
| Postmenopause | 2.02 (1.42–2.86) | <0.001 | 1.07 (0.64–1.79) | 0.803 |
| Hypertension | 2.97 (2.09–4.21) | <0.001 | 1.52 (0.96–2.38) | 0.073 |
| Diabetes | 4.52 (3.08–6.64) | <0.001 | 2.35 (1.40–3.95) | 0.001 |
| Triglyceridemia | 6.47 (4.12–10.18) | <0.001 | 3.22 (1.81–5.72) | <0.001 |
| HDL | 0.33 (0.23–0.48) | <0.001 | 0.60 (0.38–0.97) | 0.036 |
| Central obesity | 6.45 (4.48–9.27) | <0.001 | 3.67 (2.36–5.70) | <0.001 |
| Smoking | 0.93 (0.34–2.53) | 0.891 | 0.75 (0.23–2.46) | 0.628 |
| Exercise | 1.43 (1.00–2.05) | 0.052 | 1.56 (0.99–2.47) | 0.057 |
| ALT | 1.08 (1.06–1.10) | <0.001 | 1.07 (1.04–1.09) | <0.001 |
| GGT | 1.02 (1.01–1.03) | <0.001 | 1.00 (0.99–1.01) | 0.353 |
| HOMA | 2.33 (1.91–2.54) | <0.001 | 1.23 (0.97–1.56) | 0.093 |
NAFLD: nonalcoholic fatty liver disease; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; OR: odds ratio; CI: confidence interval; HDL: high density lipoprotein; HOMA: homeostasis model assessment-estimated insulin resistance.